Applications of Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulation During Regulatory Review

被引：366

作者：

Zhao, P. ^{[1
]}

Zhang, L. ^{[1
]}

Grillo, J. A. ^{[1
]}

Liu, Q. ^{[1
]}

Bullock, J. M. ^{[1
]}

Moon, Y. J. ^{[1
]}

Song, P. ^{[1
]}

Brar, S. S. ^{[1
]}

Madabushi, R. ^{[1
]}

Wu, T. C. ^{[1
]}

Booth, B. P. ^{[1
]}

Rahman, N. A. ^{[1
]}

Reynolds, K. S. ^{[1
]}

Berglund, E. Gil ^{[2
]}

Lesko, L. J. ^{[1
]}

Huang, S-M ^{[1
]}

机构：

[1] US FDA, Off Clin Pharmacol, Ctr Drug Evaluat & Res, Silver Spring, MD USA

[2] Med Prod Agcy, Efficacy & Safety 2, Uppsala, Sweden

来源：

CLINICAL PHARMACOLOGY & THERAPEUTICS | 2011年 / 89卷 / 02期

关键词：

DRUG-DRUG INTERACTIONS; IN-VITRO; TISSUE DISTRIBUTION; MIDAZOLAM CLEARANCE; HUMAN-POPULATIONS; RENAL IMPAIRMENT; STEADY-STATE; PREDICTION; VARIABILITY; LIVER;

D O I：

10.1038/clpt.2010.298

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Physiologically based pharmacokinetic (PBPK) modeling and simulation is a tool that can help predict the pharmacokinetics of drugs in humans and evaluate the effects of intrinsic (e. g., organ dysfunction, age, genetics) and extrinsic (e. g., drug-drug interactions) factors, alone or in combinations, on drug exposure. The use of this tool is increasing at all stages of the drug development process. This report reviews recent instances of the use of PBPK in decision-making during regulatory review. The examples are based on Center for Drug Evaluation and Research reviews of several submissions for investigational new drugs (INDs) and new drug applications (NDAs) received between July 2008 and June 2010. The use of PBPK modeling and simulation facilitated the following types of decisions: the need to conduct specific clinical pharmacology studies, specific study designs, and appropriate labeling language. The report also discusses the challenges encountered when PBPK modeling and simulation were used in these cases and recommends approaches to facilitating full utilization of this tool.

引用

页码：259 / 267

页数：9

共 45 条

[1] [Anonymous], 2009, DRUG INTERACTION STU
[2] Characterizing uncertainty and variability in physiologically based pharmacokinetic models: State of the science and needs for research and implementation
Barton, Hugh A.
Chiu, Weihsueh A.
Setzer, R. Woodrow
Andersen, Melvin E.
Bailer, A. John
Bois, Frederic Y.
DeWoskin, Robert S.
Hays, Sean
Johanson, Gunnar
Jones, Nancy
Loizou, George
MacPhail, Robert C.
Portier, Christopher J.
Spendiff, Martin
Tan, Yu-Mei
[J]. TOXICOLOGICAL SCIENCES, 2007, 99 (02) : 395 - 402
[3] Determination of volume of distribution at steady state with complete consideration of the kinetics of protein and tissue binding in linear pharmacokinetics
Berezhkovskiy, LM
[J]. JOURNAL OF PHARMACEUTICAL SCIENCES, 2004, 93 (02) : 364 - 374
[4] Pharmacokinetic predictions in children by using the physiologically based pharmacokinetic modelling
Bouzom, F.
Walther, B.
[J]. FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2008, 22 (06) : 579 - 587
[5] Stochastic prediction of CYP3A-mediated inhibition of midazolam clearance by ketoconazole
Chien, Jenny Y.
Lucksiri, Aroonrut
Ernest, Charles S., II
Gorski, J. Christopher
Wrighton, Steven A.
Hall, Stephen D.
[J]. DRUG METABOLISM AND DISPOSITION, 2006, 34 (07) : 1208 - 1219
[6] The use of mechanistic DM-PK-PD modelling to assess the power of pharmacogenetic studies -: CYP2C9 and warfarin as an example
Dickinson, Gemma L.
Lennard, Martin S.
Tucker, Geoffrey T.
Rostami-Hodjegan, Amin
[J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2007, 64 (01) : 14 - 26
[7] Incorporating in vitro information on drug metabolism into clinical trial simulations to assess the effect of CYP2D6 polymorphism on pharmacokinetics and pharmacodynamics: Dextromethorphan as a model application
Dickinson, Gemma L.
Rezaee, Saeed
Proctor, Nicholas J.
Lennard, Martin S.
Tucker, Geoffrey T.
Rostami-Hodjegan, Amin
[J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2007, 47 (02) : 175 - 186
[8] Physiology-Based Simulations of a Pathological Condition Prediction of Pharmacokinetics in Patients with Liver Cirrhosis
Edginton, Andrea N.
Willmann, Stefan
[J]. CLINICAL PHARMACOKINETICS, 2008, 47 (11) : 743 - 752
[9] Development and evaluation of a generic physiologically based pharmacokinetic model for children
Edginton, Andrea N.
Schmitt, Walter
Willmann, Stefan
[J]. CLINICAL PHARMACOKINETICS, 2006, 45 (10) : 1013 - 1034
[10] The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin
Gorski, JC
Jones, DR
Haehner-Daniels, BD
Hamman, MA
O'Mara, EM
Hall, SD
[J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1998, 64 (02) : 133 - 143

← 1 2 3 4 5 →